A Pilot Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Trial Profile

A Pilot Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2013

At a glance

  • Drugs Bafetinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms ENABLE
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 15 Nov 2012 Status changed from active, no longer recruiting to completed, according to a CytRx Corportion media release.
    • 15 Nov 2012 Evaluation of bafetinib in the ENABLE trial has been completed, according to a CytRx Corporation media release. CytRx plans to seek a partner for further development of bafetinib.
    • 02 Apr 2012 New source identified and integrated (M.D. Anderson Cancer Center record 2010-0175).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top